Search
Takeda Pharmaceutical Co Ltd
TAKAdd to Watchlist
18.860USD
+0.270+1.45%
Close 09-25 16:00（ET）
60.23BMarket Cap
49.15P/E TTM
After-hours 19:00 (ET)18.860USD+0.015+0.08%
After-hours 19:00 (ET)Takeda Pharmaceutical Co Ltd (TAK) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Takeda Pharmaceutical Co Ltd in the past month.
Buy
1 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
21.967USD+16.78%
TAK Analyst Recommendation Trends
In the current month, TAK has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TAK average Analyst price target in the last month is 21.967.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
TAK Analyst Rating for Peer Comparison
Updated: Sep 26, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
12
14
4
0
0
30
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Financial Forecasting
Based on analysts' estimates, TAK EPS is projected to reach 0.855 in FY2027Q2, following reported EPS of 0.220 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
FY2027Q3
Forecast
0.84
0.39
0.90
0.85
0.77
Actual
0.21
-0.74
0.22
--
--
Surprise
-75.03%
-289.81%
-75.40%
--
--
FAQs
What is Takeda Pharmaceutical Co Ltd's expected revenue for the next quarter?
Takeda Pharmaceutical Co Ltd's expected revenue is 7.47B.
What is Takeda Pharmaceutical Co Ltd's price target?
Analysts forecast that Takeda Pharmaceutical Co Ltd's price target is USD 21.97, with the highest forecast at USD 23.00 and the lowest forecast at USD 21.00.
How have Takeda Pharmaceutical Co LtdTAK's recent earnings per share performed?
The market expectation was USD 0.22, while Takeda Pharmaceutical Co LtdTAK's earnings per share (EPS) for the previous quarter was USD -0.74. EPS for the next quarter is expected at USD 0.85.
What is the analyst rating for Takeda Pharmaceutical Co Ltd?
Based on the ratings of Takeda Pharmaceutical Co Ltd's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.